Pricing Log in Create free account
Friday 6 November 2026 Export BMRN’s income statement to Excel — free account

BioMarin Pharmaceutical Inc.

BMRN Healthcare Biotechnology

BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.

Revenue
+32.0%
EPS
−296.6%
Free cash flow
−52.3%
Total debt
+599.5%

Quarter to September 2026, against a year earlier

55.89 0.23 −0.41%
Market cap
$10.9B
P/E
0.0×
Fwd P/E
32.7×
Dividend yield
—
F-score
5/9
Altman Z
5.67
Beneish M
−2.49
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

BioMarin Pharmaceutical Inc. 10-Q filed Nov 3, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:34 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 6, 2026: 14 added · 10 removed · 23 modified; 12 with only figures updated; 1 moved without change

  1. Modified · Overview

    On April 27, During 2026, we completed the acquisitionacquisitions of Amicus Therapeutics, Inc. (Amicus). The results of operations of Amicus, along with the preliminary estimated fair values and Alesta Therapeutics B.V. (Alesta). The accounting impacts of assets acquired and liabilities assumed in the acquisition, these transactions have been includedreflected in the Condensed Consolidated Financial Statements since the closing of the acquisition on April 27, 2026. Refer to Note 2 – Acquisitions for additional details related to the Amicus acquisitionthese acquisitions.

46 more changes in this Item, word by word, in Powerpack.